Background: Pain is a common complication after mixed hemorrhoids, which seriously affects the recovery of patients and prolongs the length of hospital stay. Acupoint catgut embedding has advantages in improving a variety of acute and chronic pain diseases, but there is still a lack of rigorous randomized controlled studies to verify its efficacy and safety in the treatment of postoperative pain of mixed hemorrhoids. Therefore, the purpose of this randomized controlled trial is to evaluate the clinical efficacy of acupoint catgut embedding in the treatment of postoperative pain of mixed hemorrhoids. Methods: This is a prospective randomized controlled trial to study the efficacy and safety of acupoint catgut embedding in the treatment of postoperative pain of mixed hemorrhoids. Approved by the clinical research ethics committee of our hospital, the patients were randomly divided into observation group and control group according to 1:1. The observation group received acupoint catgut embedding before the operation, while the control group received no special treatment. The efficacy and safety indexes were concerned after the operation, and the observation indexes included: resting state and visual analogue scale (VAS) score during defecation, postoperative hospitalization time, total amount of analgesic use, adverse reactions, etc. Finally, we carried on the data statistical analysis through the SPSS version 19.0. Discussion: This study will evaluate the efficacy and safety of acupoint catgut embedding in the treatment of postoperative pain of mixed hemorrhoids, and the results of this study will provide a new idea for the selection of postoperative analgesia for mixed hemorrhoids resection. Trial registration: OSF Registration number: DOI 10.17605/OSF.IO/T2ZGY.

A new nontoxic porous InIII‐based metal‐organic framework [In(Hpbic)(pbic)](DMF)2 (1) (DMF = N,N‐dimethylacetamide) was successfully prepared with 2‐(pyridin‐4‐yl)‐1H‐benzo[d]imidazole‐5‐carboxylic acid (H2pbic) as organic linker via a solvothermal process. Further, the nanostructure 1 could be obtained via a green grinding method. Nitrogen adsorption measurements revealed the presence of micropores as well as moderate high BET surface areas in the activated nanostructure 1 (1a). The drug loading experiment shows that 5‐fluorouracil (5‐Fu) is preferentially captured into the pore of the nanostructure 1a with a loading capacity of 32.6 %. Meanwhile, the controlled release of 5‐Fu in a simulated human body with liquid phosphate‐buffered saline solution was realized. In addition, the Cell Counting Kit‐8 (CCK‐8) assay was conducted to determine the inhibitory effect of 5‐Fu@1a on human colon cancer cell SW60 viability and proliferation, the results indicated the excellent anti‐cancer activity of 5‐Fu@1a in vitro. To reveal the related mechanism, the Annexin V‐FITC/PI assay and reactive oxygen species (ROS) level detection was carried out after 5‐Fu@1a treatment. Finally, the in vivo xenograft model was constructed in mice, the tumor volume, and mice body weight were recording at indicated time. The in vivo results suggested the significant inhibitory activity of 5‐Fu@1a in mice.